Journal Home
Search for

Articles in Press

Return to articles in press list

Dosimetric Analysis Of Respiratory-Gated Radiotherapy For Hepatocellular Carcinoma

Mian Xi, M.D., Li Zhang, Ph.D., Meng-Zhong Liu, M.D.Corresponding Author Informationemail address, Xiao-Wu Deng, Ph.D., Xiao-Yan Huang, Ph.D., Hui Liu, M.D.

Received 25 May 2009; accepted 8 February 2010. published online 31 May 2010.
Corrected Proof

Abstract 

The purpose of this study was to define individualized internal target volume (ITV) for hepatocellular carcinoma (HCC) using 4D computed tomography (4DCT), and to determine the geometric and dosimetric benefits of respiratory gating. Gross tumor volumes (GTVs) were contoured on 10 respiratory phases of 4DCT images for 12 patients with HCC. Three treatment plans were prepared using different planning target volumes (PTVs): (1) PTV3D, derived from a single helical clinical target volume (CTV) plus conventional margins; (2) PTV10 phases, derived from ITV10 phases, which encompassed all 10 CTVs plus an isotropic margin of 0.8 cm; (3) PTVgating, derived from ITVgating, which encompassed three CTVs within gating-window at end-expiration plus an isotropic margin of 0.8 cm. The PTV3D was the largest volume for all patients. The ITV-based plans and gating plans spared more normal tissues than 3D plans, especially the liver. Without increasing normal tissue complication probability of the 3D plans, the ITV-based plans allowed for increasing the calculated dose from 50.8 Gy to 54.7 Gy on average, and the gating plans could further escalate the dose to 58.5 Gy. Compared with ITV-based plans, the dosimetric gains with gating plan strongly correlated with GTV mobility in the craniocaudal direction. The ITV-based plans can ensure target coverage with less irradiation of normal tissues compared with 3D plans. Respiratory-gated radiotherapy can further reduce the target volumes to spare more surrounding tissues and allow dose escalation, especally for patients with tumor mobility >1 cm.

⁎State Key Laboratory of Oncology in Southern China; and †Department of Radiation Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, China

Corresponding Author InformationReprint requests to: Meng-Zhong Liu, M.D., Department of Radiation Oncology, Cancer Center, Sun Yat-sen University, No. 651 Dongfeng East Road, Guangzhou, Guangdong, China

 Mian Xi and Li Zhang contributed equally to this study.

PII: S0958-3947(10)00033-6

doi:10.1016/j.meddos.2010.03.006